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Abstract The six proteins of the CCN family have
important roles in development, angiogenesis, cell motility,
proliferation, and other fundamental cell processes. To date,
CCN5 distribution in developing rodents and humans has
not been mapped comprehensively. CCN5 strongly inhibits
adult smooth muscle cell proliferation and motility. Its anti-
proliferative action predicts that CCN5 would not be
present in developing tissues until the proliferation phase
of tissue morphogenesis is complete. However, estrogen
induces CCN5 expression in epithelial and smooth muscle
cells, suggesting that CCN5 might be widely expressed in
embryonic tissues exposed to high levels of estrogen.
9–16 day murine embryos and fetuses and 3–7 month
human fetal tissues were analyzed by immunohistochemis-
try. CCN5 was detected in nearly all developing tissues.
CCN5 protein expression was initially present in most
tissues, and at later times in development tissue-specific
expression differences were observed. CCN5 expression
was particularly strong in vascular tissues, cardiac muscle,
bronchioles, myotendinous junctions, and intestinal smooth
muscle and epithelium. CCN5 expression was initially
absent in bone cartilaginous forms but was increasingly
expressed during bone endochondral ossification. Wide-
spread CCN5 mRNA expression was detected in GD14.5
mice. Although CCN2 and CCN5 protein expression
patterns in some adult pathologic conditions are inversely
expressed, this expression pattern was not found in
developing mouse and human tissues. The widespread
expression pattern of CCN5 in most embryonic and fetal
tissues suggests a diverse range of functions for CCN5.
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Introduction
CCN5 is a member of the cysteine-rich 61/connective tissue
growth factor/nephroblastoma-overexpressed (CCN) family
of genes (Perbal and Takigawa 2005b). The six members of
this family are matricellular proteins that have important
functions in numerous cell and physiologic processes,
including embryonic development, cell motility and prolif-
eration, angiogenesis, and extracellular matrix biology
(Perbal and Takigawa 2005a; Leask and Abraham 2006;
Perbal 2004; Rachfal and Brigstock 2005). CCN5, previ-
ously known as WISP-2 (Pennica et al. 1998), rCop-1
(Zhang et al. 1998), COP-1 (Delmolino et al, 2001), HICP
(Delmolino et al, 1997), and CTGF-L (Kumar et al. 1999),
is highly conserved among vertebrates and is the only CCN
protein that lacks the fourth C-terminal domain (Gray and
Castellot 2005). In adult rodents, CCN5 mRNA is highly
expressed in the aorta, heart, brain, spleen, lung, skeletal
muscle, and uterus, and at lower levels in the spleen, liver,
kidney, and testis (Delmolino et al. 2001; Mason et al.
2004a).
Originally discovered as a heparin-induced gene in
vascular smooth muscle cells (SMC), CCN5 behaves as a
growth-arrest-specific gene in this cell type. CCN5 is
highly expressed in quiescent, non-proliferating rat aortic
SMC and expression levels drop rapidly as cells are
stimulated to re-enter the cell cycle. SMC CCN5 expression
decreases in uterine fibroids and after vascular injury, two
in vivo models of SMC proliferation (Delmolino et al.
2001; Lake et al. 2003; Mason et al. 2004b). CCN5 over-
expression inhibits SMC proliferation, motility, and inva-
siveness in vitro, and CCN5 knock-down causes opposite
effects (Lake et al. 2003; Lake and Castellot 2003; Mason
et al. 2004b). CCN5 is strongly up-regulated by estrogen in
both SMC and epithelial cells (Fritah et al. 2006; Gray and
Castellot 2005; Inadera et al. 2000; Mason et al. 2004a).
There are several pathologic conditions in which CCN2
and CCN5 have opposite expression patterns, including
asthma (unpublished observations; van den Brule S et al.
2007) uterine leiomyoma (fibroids) (De Falco et al. 2006;
Mason et al. 2004b), and hepatocellular carcinoma (Cervello
et al. 2004; Hirasaki et al. 2001). However, in other diseases,
including arthritis (Manns et al. 2006; Tanaka et al. 2005)
and viral hepatitis (Fukutomi et al. 2005; Shin et al. 2005),
CCN2 and CCN5 are similarly expressed. CCN2 and CCN5
have opposite expression patterns in vascular SMC. CCN2
over-expression induces vascular SMC proliferation and
increases MMP-2 expression, and CCN5 over-expression
reduces proliferation and MMP-2 expression. CCN5 expres-
sion decreases and CCN2 expression increases in vascular
SMC during the proliferative phase of balloon angioplasty
injury (Ando et al. 2004; Fan et al. 2000; Fan and Karnovsky
2002; Lake et al. 2003; Lake and Castellot 2003). Opposite
expression patterns of CCN2 and CCN5 in vascular SMC
and in some proliferative disease states suggest that they
might have complementary or opposite expression patterns
in the developing embryo.
The temporospatial embryonic expression patterns of
CCN1, CCN2, CCN3, and CCN4 have been comprehen-
sively analyzed in developing mammals, (French et al.
2004; Friedrichsen et al. 2003; Ivkovic et al. 2003; Kireeva
et al. 1997; Kocialkowski et al. 2001; Lopes et al. 2004;
Natarajan et al. 2000; O’Brien and Lau 1992; Surveyor
et al. 1998; Surveyor and Brigstock 1999) however, the
expression pattern of CCN5 has not been explored. The
strong anti-proliferative and anti-motility activity of CCN5
against cultured SMC (Delmolino et al. 2001; Lake et al.
2003; Mason et al. 2004b) predicts that, at least in SMC,
CCN5 expression should be low in early development when
cell proliferation and motility is high, and CCN5 expression
should increase in some embryonic tissues later in develop-
ment as cells stop proliferating and enter a more differenti-
ated state. On the other hand, embryos develop in a very
estrogen-rich environment, and CCN5 is strongly induced by
estrogen (Banerjee et al. 2003; Fritah et al. 2006; Gray and
Castellot 2005; Inadera et al. 2000; Mason et al. 2004a, b),
thus predicting that CCN5 should be present in most or all
embryonic tissues in response to this stimulus.
To resolve the alternative outcomes predicted by the
anti-proliferative and estrogen-responsive nature of CCN5,
we examined the expression patterns of CCN5 protein and
mRNA and compared them to CCN2 protein expression
patterns in developing mouse and human tissues. We
observed widespread expression of CCN5 and CCN2 early
in development that becomes increasingly restricted close
to parturition. In general, we found that while CCN2 has a
more restricted expression pattern than CCN5, many
developing cell types and tissues express both proteins.
These findings have important implications for the biologic
and physiologic roles of CCN5.
Materials and methods
Animals
Animal protocols were reviewed and approved by The
Institutional Animal Care and Use Committee at Tufts
University (Boston, MA). C57BL/6J mice were obtained
from Charles River Laboratories (Wilmington, MA). Food
and water were available ad libitum. Mouse gestational
ages were confirmed by comparison to a mouse develop-
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ment atlas (Kauffman 1992). Mice of gestational age
9–13 days post coitum are referred to as embryos (E9–
E13). Older developing mice are referred to by gestational
day (GD14–GD16).
Immunohistochemistry
Paraffin-embedded 7 μm sagittal sections of C57BL
embryos and fetuses (FD Neurotechnologies, Baltimore,
MD) and paraffin-embedded 5 μm sections from tissue
cores in a human normal fetus tissue array (BE01014 and
BE01015; US Biomax, Rockville, MD) were cleared with
xylene. Endogenous peroxidase activity was quenched by
treatment with two changes of 0.6% hydrogen peroxide
(H2O2) in ethanol for 5 min. The slides were then
rehydrated and treated with the Avidin/Biotin Blocking
Kit (Vector Laboratories) in blocking serum (4% bovine
serum albumin and 2% goat serum in phosphate-buffered
saline) and then incubated in primary antibody in blocking
serum overnight at 4°C. CCN5 protein was detected using a
well characterized, highly specific, peptide affinity-purified
rabbit polyclonal antibody to a polypeptide fragment from
amino acids 103–117 of the von Willebrand Factor-C
(VWC) domain of CCN5 (Gray and Castellot 2005; Lake
et al. 2003; Lake and Castellot 2003; Mason et al. 2004a).
This antibody is routinely used in the laboratory to follow
expression of the full-length 27 kDa CCN5 protein on
western blot (Gray and Castellot 2005; Lake et al. 2003;
Lake and Castellot 2003; Mason et al. 2004a). CCN2
protein was detected using a well characterized, peptide
affinity-purified rabbit polyclonal antibody to polypeptide
fragment amino acids 223–348 from the thrombospondin-1
(TSP) and carboxy-terminal (CT) domains of mouse CCN2
(ab6992; Abcam, Cambridge, MA). Purified rabbit immu-
noglobulin IgG was used as a negative control (Biomeda,
Foster City, CA). All negative controls completely lacked
brown staining. The anti-CCN2 antibody has been used
previously in numerous immunohistochemical studies
(Candido et al. 2003; Dean et al. 2005; Finckenberg et al.
2003; Razzaque et al. 2003). Antigen retrieval by boiling
slides in 10 mM citric acid pH 6.0 did not alter CCN5 or
CCN2 staining or intensity in paraffin sections and thus was
not performed in this study (data not shown). Previous reports
(CCN2 reports listed above, Lake et al. 2003 for CCN5) of
immunohistochemistry with these CCN2 and CCN5 anti-
bodies on paraffin sections have also not employed antigen
retrieval. Slides were developed using the Vectastain Elite
ABC kit (Vector Laboratories, Burlingame, CA) and the
3,3′-diaminobenzidine (DAB) substrate kit (Vector Labora-
tories) and counterstained with Harris modified hematoxylin
with acetic acid (Fisher). All slides were dehydrated and
embedded in permanent mounting medium (#13510; DPX
Mountant; Electron Microscopy Sciences; Hatfield, PA) and
photographed using a microscope (Zeiss Axioscope) and a
digital camera system (SPOT; Diagnostic Instruments).
Antibody concentrations and substrate exposure times were
carefully titrated to minimize artifacts and ensure that the
staining intensities produced by both antibodies were similar.
All directly compared images are from slides processed in a
single experiment with a matched negative control (purified
rabbit immunoglobulin IgG).
Reverse transcriptase PCR (RT-PCR)
Two pregnant female GD14.5 mice were sacrificed with
carbon dioxide (CO2) overdose. Fetuses were dissected and
immediately placed in RNA later (QIAGEN, Valencia, CA)
and stored at −20°C. The dissected tissues were later
removed from storage and 10 mg of each tissue was
homogenized using a rotor/stator homogenizer (Fisher
Scientific, Pittsburgh, PA). RNA isolation was performed
using the RNeasy Mini kit (QIAGEN). DNA was removed
using RQ1 RNase-Free DNase (Promega, Madison, WI),
and reverse transcription was performed using the RETRO-
script kit (Ambion, Austin, TX). All assays were performed
according to the manufacturer’s protocol. Control reactions
with no reverse transcriptase were used to check for
genomic DNA contamination in each sample. PCR was
performed using the HotStarTaq Master Mix kit (QIAGEN)
with 95°C 15 min polymerase activation step followed by
35 cycles of 94°C 30 sec/50 C 30 sec/72°C 1 min and final
72°C 10 min extension step and products were examined
on a 1.5% agarose gel containing ethidium bromide.
Primers were purchased from Integrated DNATechnologies
(IDT, Coralville, IA). The sense CCN5 (GenBank Acces-
sion no. GI 4028578) primer consisted of the DNA
sequence 5′-ATACAGGTGCCAGGAAGGTG-3′ (position
707–726), and the sequence of the anti-sense CCN5 primer
was 5′-GTTGGATACTCGGGTGGCTA-3′ (position 913-
932). After PCR, these primers produced a 225 bp (base
pairs) DNA fragment that included the exon 4–5 (VWC-
TSP) boundary in order to prevent amplification of
genomic DNA sequence. The amplified DNA fragment
was purifed by electrophoresis and the QIAquick Gel
Extraction kit (QIAGEN) and sequenced by the Tufts
University Core Facility (Boston, MA) to verify its identity.
A plasmid containing mouse CCN5 cDNA was used as a
positive control for PCR. Both water and mRNA not treated
with reverse transcriptase enzyme were used as negative
controls. PCR was also performed with the above con-
ditions for the reference gene TATA box binding protein
(Tbp) (GenBank Accession no. GI 2052376) with the
following primers sense 5′-GCCTCTCAGAAGCAT
CACTA-3′ and anti-sense 5′-GCCAAGCCCTGAGCA
TAA-3′. PCR produced a 166 bp DNA fragment that
included an exon–exon boundary (Willems et al. 2006).
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Results
We determined the temporal and spatial expression
pattern of CCN5 during embryonic and fetal develop-
ment using a well-characterized anti-CCN5 antibody
(Lake et al. 2003; Mason et al. 2004a). Mouse embryos
and fetuses were obtained at time points ranging from E9
to GD16 and prepared as described in “Materials and
methods”. Sections from human fetuses at 3 to 7 months
of gestation were obtained and stained as described in
“Materials and methods”. We compared the expression
patterns of CCN5 with those of CCN2, a prototypical
CCN family member containing all four domains. CCN2
exhibits a biological activity profile that is almost
completely opposite that of CCN5 in smooth muscle cells
(Ando et al. 2004; De Falco et al. 2006; Fan et al. 2000;
Fan and Karnovsky 2002; Lake et al. 2003; Lake and
Castellot 2003; Mason et al. 2002). No color reaction was
detected when pooled rabbit IgG was used in place of
primary antibody. Descriptions of staining intensity are
intended for comparing protein levels detected for one
protein only, not to compare the relative protein levels of
CCN2 and CCN5. The two antibodies would not be
expected to have identical affinities for their antigens and
thus cannot be directly compared in this manner.
Early embryonic development
Immunohistochemistry results demonstrate that CCN5 is
widely expressed throughout early embryonic development
of the mouse. CCN5 was expressed in tissues of ectoder-
mal, mesodermal, and endodermal origin (Fig. 1 and Supp.
Fig. 1). In general, CCN2 and CCN5 staining was similar
and detected in all embryonic organs at E9, E10, and E11
(Supp. Fig. 1 and data not shown; at high magnification
specific staining is increased relative to negative control for
both CCN2 and CCN5 in all organs including brain in E9
embryos). As organs further differentiated at E12 and later,
some cell types increased and others decreased CCN5
expression. Beginning at E12, staining differences were
detected. CCN5 was present in a larger number of cell types
than CCN2 in GD14–16 mice.
Fig. 1 CCN5 expression during
E12–GD16 mouse development.
Mouse embryonic and fetal sagit-
tal sections from a E12,
b GD14 and c GD16 developing
mice. Negative control (c right) –
pooled rabbit IgG applied in





CCN2 left, CCN5 right c CCN2
left, CCN5 middle, Control right.
Scale Bars=1 mm. Scale Bars
and labels on CCN5 panels also
apply to CCN2 and IgG panels.
CCN5 and CCN2 immunoreac-
tivity shown by brown staining.
Nuclei are shown by hematoxy-
lin (blue) staining. Tissue sec-
tions treated with pooled rabbit
IgG gave no detectable staining
(c and data not shown)
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In the sections below, we present comparisons of CCN5
and CCN2 expression patterns in mouse and human tissues
of the major organ systems at several time points in
embryonic and fetal development.
Cardiovascular system
Mouse The cardiovascular system is the first functional
organ system in developing mammalian embryos. CCN5
was abundantly expressed in the endothelium and smooth
muscle of veins and arteries, while CCN2 was detectable at
very low levels (Figs. 2a, 4b, and Supp. Fig. 2a,b). Higher
levels of both CCN2 and CCN5 were detected in the apex
of the developing heart during E12–GD14 when compared
to myocardial expression levels. At GD16, CCN5 expres-
sion in myocardium was uniform. In contrast, at GD16
CCN2 expression was decreased throughout the myocardi-
um relative to GD14 expression (Fig. 2b–d, Supp. Fig. 2c).
Neither CCN2 nor CCN5 was concentrated at the apex at
GD16 (data not shown). At E12, CCN5 was present at
lower levels in the forming atrioventricular septum than in
myocardium which demonstrated uniform levels of CCN5
(Fig. 2b). CCN5 levels were very low and CCN2 was
absent in the developing cardiac valves (Fig. 2d). At GD14,
CCN5 levels were lower in aorta when compared to the
pulmonary arterial trunk (Fig. 2d). Mouse umbilical vessels
expressed CCN5 and CCN2 (Fig. 2e).
Human CCN5 was detected throughout the human fetal
myocardium, endothelium and smooth muscle of coronary
arteries and veins and to a lesser extent in other large
vessels at 4 months of gestation (Fig. 2f, Supp. Fig. 2d).
CCN2 expression was low in these fetal cardiovascular
tissues. The smooth muscle and endothelium of human
umbilical vessels displayed a high level of CCN2 and a
moderate level of CCN5 (Supp. Fig. 2e).
Respiratory system
Mouse Lung development between GD14–GD16 is con-
sidered the pseudoglandular period, corresponding to weeks
Fig. 2 CCN5 expression during
cardiovascular development.
a GD16 artery from lung. b E12
mouse heart. c,d GD14 mouse
heart. e GD14 mouse umbilical
vessels. f Human 5 month
myocardium and coronary ves-
sels. Negative control (f right) –
pooled rabbit IgG applied in
place of primary antibody.
A=Artery; Ao=Aorta; CV=
Coronary Vessels; PA=Pulmo-




a–e CCN2 left, CCN5 right. f
CCN2 left, CCN5
middle, Control right. Scale
Bar=10 μm (a) Scale Bars=
100 μm (b–f). Tissue sections
treated with pooled rabbit IgG
gave no detectable staining
(f and data not shown)
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5–17 in human development (Van Tuyl and Post 2003;
Volpe et al. 2003). CCN5 was present in GD14 and GD16
bronchial epithelium and in GD16 mesenchymal cells
surrounding branching bronchioles (Fig. 3a–c). In contrast,
CCN2 was present only in the bronchiolar epithelium and
not in the surrounding mesenchyme. Some terminal ends of
actively branching bronchioles displayed very high levels
of CCN2 at GD14 (Fig. 3a). At GD16, some bronchiolar
terminal ends demonstrated little or no CCN2 and others
expressed higher levels of CCN2, while all bronchiolar
terminal ends expressed CCN5 (Fig. 3b). CCN5 was
present in the epithelial and mesenchymal cell layers of
larger bronchioles, and CCN2 was absent (Fig. 3c). CCN2
was present mostly in actively growing and branching
bronchi, but not in some terminal ends of actively
branching bronchioles and in the bronchiolar epithelium
after larger bronchioles are established. In contrast, CCN5
was expressed both in the larger bronchioles and through-
out actively branching bronchioles.
Human Fetal lung tissue at 5 months of development
demonstrated CCN5 at low but uniform levels in epithelial
and mesenchymal cells, and no CCN2 staining (Fig. 3d). At
this time in development (the canalicular period), the lung
Fig. 3 CCN5 expression during
lung development. a GD14
mouse lung. Inset shows stain-
ing in epithelial cells of bron-
chiole. b GD16 mouse lung
actively branching bronchioles.
c GD16 larger bronchi that are
no longer branching. d Human
5 month fetal lung. ep=Epithe-
lial Cells me=Mesenchymal
Cells. a–c CCN2 left, CCN5
right. Scale Bars=50 μm
(a,b,c). Scale Bars=100 μm (d).
Tissue sections treated with
pooled rabbit IgG gave no de-
tectable staining (data not
shown)
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has finished forming the bronchial tree and is forming the
acini, capillary network, and alveolar type I and II cells
(Wert 2004).
Musculoskeletal system
Mouse CCN5 was detected in GD14–16 mouse skeletal
muscle (Fig. 4a–b). CCN5 staining was particularly strong
at myotendinous junctions, beginning in GD14 and becom-
ing pronounced by GD16. In contrast, GD14–16 skeletal
muscle displayed very little CCN2 and it did not accumu-
late at myotendinous junctions. Both CCN2 and CCN5
staining was present in chondrocytes during endochondral
ossification (Fig. 4b–c). Hyaline cartilage in the resting
zones displayed neither CCN2 nor CCN5. CCN5 was
present in the chondrocytes of the proliferating, hypertro-
phic, and calcification zones, and CCN2 was seen primarily
in the chondrocytes of the hypertrophic and calcification
zones. In addition, perichondrial cells expressed CCN5
(Fig. 4c).
Human In the human fetus at 5 months of gestation, CCN5
was detected at a low level in skeletal muscle (Supp.
Fig. 3a). The human fetal samples analyzed did not include
myotendinous junctions. CCN2 was not detected in human
fetal osteocytes or osteoclasts (Fig. 4d and Supp. Fig. 3b).
In contrast, CCN5 staining was detected in osteoclast nuclei
and absent in osteocytes (Fig. 4d and Supp. Fig. 3b).
Gastrointestinal system
Mouse In GD14–16 mouse liver, both CCN2 and CCN5
staining were detected in hepatocytes but not hematopoietic
stem cells (Fig. 5a and data not shown). Neutrophils
express CCN5 but not CCN2.
The developing small intestine of the mouse expressed both
CCN2 and CCN5. At E12 (Fig. 5b) CCN2 staining was
highly expressed in intestinal epithelium, lower at GD14
(Fig. 5c), and then much weaker by GD16 (Fig. 5d). CCN2
staining was very low in intestinal smooth muscle throughout
all of the time points examined. CCN5 was detected at low
levels in intestinal smooth muscle and epithelium beginning
at E12 (Fig. 5b), at moderate levels at GD14 (Fig. 5c), and at
intermediate levels in GD16 fetuses (Fig. 5d).
Fig. 4 CCN5 expression in de-
veloping bones and skeletal
muscle. a GD14 skeletal muscle.
b GD16 skeletal muscle and
bone. c GD16 rib. d Human







Muscle. a–d CCN2 left, CCN5
right. Scale Bars=100 μm
(a,b,c). Scale Bars=20 μm (d).
Tissue sections treated with
pooled rabbit IgG gave no de-
tectable staining (data not
shown)
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Human Human fetal hepatocytes at 4 months of develop-
ment revealed moderate CCN2 and CCN5 staining
(Fig. 5e). However, at 5 months of gestation, fetal
hepatocytes revealed lower levels of CCN2 and higher
levels of CCN5 than observed at 4 months (Fig. 5f). Liver
hematopoietic stem cells do not express CCN5 or CCN2.
Analysis of CCN2 and CCN5 protein expression
patterns in the developing human intestinal tract revealed
a gradation of expression among different sections of the
digestive tract. CCN2 and CCN5 were present at moderate
levels in the esophagus at 6 months (Fig. 5g); in this
structure both proteins were detected in the muscularis
mucosae and muscularis externa. CCN2 and CCN5 were
also expressed in the esophageal epithelium, and absent in
the lamina propria. Other regions of the human fetal
intestine were examined at 5 months. CCN5 was detected
in the stomach musculature and at low levels in the
epithelium and lamina propria at 5 months; CCN2 staining
was absent in the stomach (Supp. Fig. 4a). CCN5 staining,
but not that of CCN2, was detected in the smooth muscle
and intestinal epithelium of the small intestine at 5 months
(Supp. Fig. 4b). CCN5 staining was present uniformly
throughout the gallbladder smooth muscle and epithelium,
and CCN2 staining was absent (Supp. Fig. 4c). CCN5
staining was detected in the smooth muscle of the colon
(Fig. 5h), and CCN2 was low except for the first few layers
of intestinal smooth muscle that face the lumen. Both
CCN2 and CCN5 were absent in the base of the intestinal
crypts (the location of proliferating colonic epithelium) and
highly expressed in the tips of the villi (the cells that have
moved away from the crypts and are no longer proliferat-
ing). CCN5 was detected at very low levels in the colon
lamina propria, and CCN2 was absent (Fig. 5h). In the
rectum, CCN5 was detected at low levels in smooth
muscle, lamina propria, and non-proliferating epithelium;
CCN2 was not present in these tissues (Supp. Fig. 4d).
Kidney and urogenital system
Mouse In early mouse kidney development (E12), meta-
nephric tubules express CCN5 and CCN2 (Fig. 6a) in
tubule terminals rather than uniformly throughout the
tubule cells. CCN5 was expressed in glomerular mesangial
cells, tubules, blood vessels, and collecting ducts, while
CCN2 was detected only in tubules at GD 16 (Fig. 6b–d,
Supp. Fig. 2b). Glomerular endothelial cells do not display
any CCN5, in contrast to endothelial cells of larger vessels.
Fig. 5 CCN5 expression during
intestinal development. a GD16
mouse liver. b E12 mouse in-
testine. c GD14 mouse intestine.
d GD16 mouse intestine
(longitudinal section). e Hu-
man 4 month fetal liver. f Human
5 month fetal liver. g Human
6 month fetal esophagus. h Hu-
man 5 month fetal colon. EP=
Intestinal Epithelium; Hep=
Hepatocytes; HSC=Hematopoi-
etic Stem Cells; Neu=Neutrophil;
SM=Intestinal Smooth Muscle.
a–h CCN2 left, CCN5 right.
Scale Bars=50 μm (a,e,f). Scale
Bars=100 μm (b–d, g–h). Tissue
sections treated with pooled
rabbit IgG gave no detectable
staining (data not shown)
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GD14 mouse bladder smooth muscle, mesenchyme, and
urothelium displays CCN5 but CCN2 was only detected in
the urothelium (Fig. 6d). In the mouse bladder at GD16, the
urothelium and smooth muscle display CCN2 and CCN5
(Fig. 6e).
The germinal epithelium and ovary reveal CCN5 staining at
GD14 (Fig. 6f). Higher levels of CCN5 staining and low
levels of CCN2 staining were found in the ovary and
epithelial cells and glands of the reproductive tract at GD16
(Fig. 6g).
Human In the human fetal kidney at 5 months, CCN5 staining
was detected in mesangial cells, tubules, and glomeruli
(Fig. 6h). CCN2 expression was very low in these structures.
Low levels of CCN5 staining were detected in the
developing human reproductive system at 5 months, with
the exception of high levels in placental trophoblasts
(Fig. 6i). CCN5 staining was absent in regions where the
chorionic villi fused together and branched. Weak CCN5
staining was detected in testicular Leydig cells (Fig. 6j),
uterus (Fig. 6k), ovarian stroma (Fig. 6l), fallopian tube
(Fig. 6m), and epididymis (Fig. 6n). In contrast, CCN2 was
absent in all developing human reproductive organs
examined (data not shown).
Endocrine and immune organs
Mouse In GD16 mouse thyroid gland (Fig. 7a), very low
levels of CCN2 and moderate levels of CCN5 were
observed. CCN5 staining was detected on the colloidal side
of developing thyroid follicles, suggesting that the thyroid
follicle cells produce and excrete CCN5. Both CCN5 and
CCN2 were detected in the connective tissue of the adrenal
capsule (Fig. 7b). CCN5 staining was observed in the nuclei
of some adrenal cells (Fig. 7b, inset). The pancreas in
developing mice displayed low levels of CCN5 and CCN2 in
the exocrine ducts. CCN2 and CCN5 levels were extremely
low or absent in thymus and spleen (data not shown).
Fig. 6 CCN5 expression in de-
veloping urogenital system. a
E12 mouse kidney. b,c GD16
mouse kidney. d GD14 mouse
bladder. e GD16 mouse bladder.
f GD14 mouse ovary. g GD16
mouse ovary and reproductive
tract. h Human 5 month fetal
kidney. i Human 5 month pla-
centa. j Human 5 month
fetal testis. k Human 5 month
fetal uterus. l Human
5 month fetal ovary. m Human
5 month fetal fallopian tube.
n Human 5 month fetal
epididymis. filled triangle=High
or empty triangle=low CCN
protein expression in metaneph-
ric tubules. Br=branch point of
chorionic villi with absent
CCN5 staining; CD=collecting






urothelium. a–h CCN2 left,
CCN5 right. i–n CCN5. Scale
Bars=50 μm. Tissue sections
treated with pooled rabbit IgG
gave no detectable staining (data
not shown)
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Human In 5 month human fetal thyroid, (Fig. 7c), moderate
levels of CCN5 were observed, and CCN2 was not
detectable. In the 5 month human fetal adrenal gland,
CCN5 was present in the zona fasciculata, the region of the
gland that makes cortisol, and very low in the zona
glomerulosa, the region that produces aldosterone
(Fig. 7d). No CCN2 staining was observed in the human
fetal adrenal gland. Human fetal pancreas demonstrated
only CCN5, and not CCN2, in the exocrine ducts. Very
little CCN2 or CCN5 was detected in fetal human thymus
and spleen (data not shown).
Nervous system and skin
Mouse Both CCN2 and CCN5 were widely distributed in
the brain of E12 mouse embryos (Fig. 8a). Expression of
both proteins was much more restricted in the later GD14
(Fig. 8b) and GD16 fetuses (Fig. 8c). Many cells in the
developing mouse brain and spinal cord demonstrated
CCN2 and CCN5 predominantly and strongly in the
nucleus of neurons (Fig. 8d), in contrast to most cell types
where CCN5 is found primarily in cytoplasm or tightly
bound to the outer surface of the cell membrane. Both
CCN5 and CCN2 were present in the choroid plexi,
particularly at GD16 (Fig. 8b–c).
Both CCN2 and CCN5 were present in the developing
GD16 mouse vibrissae (Fig. 8e). CCN5 was observed in
both the inner and outer root sheath layer of cells, and
CCN2 was limited to the inner sheath. Both CCN2 and
CCN5 were detected at high levels in the developing
epidermis of GD16 mouse (Fig. 8f).
In the mouse eye at GD16, CCN5 and CCN2were detected
in the fused eyelid and corneal epithelium (Fig. 8g). CCN5,
and not CCN2, was detected in the mouse corneal stroma.
Human Neither CCN5 nor CCN2 was found in the human
fetal brain at 4 months (data not shown). This may be due to
species differences between mouse and human. Alternatively,
because only cores of tissue were examined it is possible that
CCN2 or CCN5 was present in the developing human brain in
other regions or at other time points not examined in this study.
Both CCN2 and CCN5 were present in human fetal hair
follicles at 5 months (Fig. 8i), with CCN5 found in both the
inner and outer root sheath layer of cells and CCN2 limited
to the inner sheath. Both CCN2 and CCN5 were detected a
high levels in the developing epidermis of 5 month human
fetal skin (Fig. 8i). In the human fetal eye at 4 months, the
rod/cone photoreceptor segment of the retina displayed
high levels of CCN5, but not CCN2 (Fig. 8j). Low levels of
both CCN2 and CCN5 were detected in the afferent nerve
fibers. We also noted very lightly stained material just
under the retinal pigmented epithelium in what appears to
be the cytosol of the retinal pigmented epithelia. This
structure appears very early on in development (as do the
retinal ganglia cells), and thus this observation fits with our
hypothesis that CCN5 may limit proliferation of these two
layers as the photoreceptors are usually in a highly
proliferative stage at this point in development.
Expression of CCN5 mRNA
Immunohistochemical analysis provides the most accurate
representation of the location of the CCN5 protein. It is
possible that this proteins is translated, secreted, and then
distributed to its target cells and tissues. We compared the
sites of CCN5 protein translation and its final distribution
by analyzing mouse fetal tissues for CCN5 mRNA. Organs
from GD14.5 mice were collected and mRNA prepared for
analysis by RT-PCR. CCN5 mRNA was found in every
fetal organ examined, including lung, limbs and tails,
Fig. 7 CCN5 expression in en-
docrine organs. a Mouse GD16
thyroid gland. b Mouse GD16
adrenal gland. Insets magnified
to show nuclear CCN5 staining
in adrenal gland cells. c Human
5 month fetal thyroid gland. d
Human 5 month fetal adrenal
gland. F=thyroid follicle; ZF=
zona fasciculata; ZG=zona glo-
merulosa. a–d CCN2 left, CCN5
right. Scale Bars=100 μm (a,b,
d). Scale Bars=25 μm (c). Tis-
sue sections treated with pooled
rabbit IgG gave no detectable
staining (data not shown)
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umbilical cord, intestine, heart, liver, carcass, and head
(Fig. 9). CCN5 mRNA was also demonstrated in the
maternal placenta. We previously demonstrated CCN5
mRNA in the intact rat uterus and aorta and in cultured
human uterine SMC and rat aortic SMC and endothelial
cells (Delmolino et al. 2001; Mason et al. 2004a). These
results suggest that the observed immunohistochemical
findings in GD14 mice are the result of local synthesis of
CCN5 mRNA, rather than synthesis in one organ and
subsequent protein distribution to other sites.
Discussion
In this report, we comprehensively examined the distribution
pattern of CCN5 and CCN2 protein during embryonic and
fetal development of the mouse, comparing it to the
expression pattern in human fetal tissues. We examined
CCN5 mRNA levels in selected organs in the GD14.5 mouse,
and provide a comparison of all of the currently available data
from similarly comprehensive studies on developing mam-
malian mRNA and protein distribution for all of the CCN
family members (Table 1). We found that CCN5 protein is
present in most or all cells in early embryos, and then tissue-
specific CCN5 expression differences appear as embryos
age. CCN5 expression was not restricted to cell types of a
particular embryonic germ layer lineage.
While the hypothesis that high estrogen levels cause
high CCN5 expression in embryonic tissues is attractive, at
least two lines of evidence suggest that this is not the entire
explanation. First, numerous cell types in GD16 fetuses
produce little or no CCN5 protein when high estrogen
levels are present (17-β estradiol levels in mouse pregnancy
are stable at 15–25 pg/ml between days 2–16) (McCormac
and Greenwal 1974). Second, despite several independent
attempts by both our group and other laboratories to
produce CCN5 knockout mice, no laboratory has produced
either hemizygous or homozygous CCN5 knockout animals,
Fig. 8 CCN5 expression in de-
veloping brain, hair, skin, and
eyes. a E12 mouse brain. b
GD14 mouse brain. c GD16
mouse brain. d GD16 spinal
cord. e GD16 mouse whisker.
f GD16 mouse skin. g GD16
mouse eye. h Human 5 month
fetal hair follicle. i Human
5 month fetal skin. j Human
4 month fetal retina Af=afferent
nerve fibers; C=choroid; IRS=
inner root sheath; ORS=outer
root sheath; PR=photoreceptors.
a–k CCN2 left, CCN5 right.
Scale Bars=100 μm (a–f, i,j).
Scale Bars=50 μm (g,h). Tissue
sections treated with pooled
rabbit IgG gave no detectable
staining (data not shown)
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suggesting that CCN5 is necessary for early development.
Furthermore, primary human bone-marrow derived mesen-
chymal stem cells initially express high levels of CCN5, and
then express CCN5 at high, medium, or low levels
respectively as the cells undergo differentiation into osteo-
genic, chondrogenic, and adipogenic lineages (Schutze et al.
2005). This mirrors our observation that the less differen-
tiated cells of early embryos express high levels of CCN5,
and as cells further differentiate, CCN5 expression levels
generally decline and vary among different cell types. Thus,
CCN5 is not a general marker of quiescence and maturation
as originally predicted due to our observations of SMC
expression patterns, but increases with differentiation in
some cell types and decreases in others.
Though this and other published reports generally agree on
the distribution of CCN2 in most developing tissues, there are
several discrepancies among published reports of CCN2
protein ormRNA expression that remain unresolved (Table 1).
Discrepancies between ISH and IHC data can occur for a
number of reasons, including post-transcriptional modifica-
tions that alter mRNA translation or stability, and post-
translational processing that alters protein maturation,
accumulation, or degradation. Discrepancies in mRNA or
protein distribution may be due to differences in sensitivity
of the methods. For example, Kireeva et al (1997) used a
peroxidase-conjugated secondary antibody and found less
CCN2 in many organ systems than we and Surveyor and
Brigstock (1999) did using the more sensitive avidin–biotin
technique. Discrepancies may also be due to differences in
the affinity, avidity, or epitope availability of the specific
CCN2 antibodies used, as well in the specific fixation
techniques used. CCN2 distribution in our study was
mapped with an antibody against amino acids 223–348 of
the CCN2 protein, while previous efforts employed anti-
bodies against amino acids 165–200 (Kireeva et al. 1997)
and amino acids 80–93 (Surveyor and Brigstock 1999) of
the CCN2 protein. We have also used this latter antibody
and see the same CCN2 expression pattern as we found
with the aa223–348 antibody testing identical tissues and
fixation conditions.
We initially hypothesized that CCN2 and CCN5 would
have complementary expression patterns. With a few
exceptions, we found that cell types expressing CCN2 also
express CCN5. However, CCN5 was highly expressed in
many cells where CCN2 expression was low or absent, for
example in developing skeletal muscle myotendinous
junctions. We conclude that while in certain disease
systems CCN2 increases in pathologies where CCN5
decreases that this pattern is not generally true for
developing human and mouse tissues.
We observed CCN5 protein in the SMC and endothelial
cells of large vessels, as was expected due to previous
observations that both CCN5 protein and mRNA are
present in vascular smooth muscle cells and endothelium
of aorta and other larger vessels (Delmolino et al. 2001;
Gray and Castellot 2005; Lake et al. 2003). Although we
predicted that CCN5 levels would be low in developing
vascular smooth muscle because the embryo is actively
growing, we found that CCN5 was consistently expressed
in VSMC, suggesting that the carefully controlled cell
proliferation required for embryonic growth does not
require an environment with low CCN5 levels. We also
observed lower CCN5 expression in the aorta relative to
that seen in the pulmonary artery, suggesting that CCN5
protein levels in VSMC may be modulated by exposure to
different mechanical forces or arterial pressure as has been
described for CCN1 (Grote et al. 2004).
In the developing lung, the variable expression of
CCN2 in terminal bronchiolar segments may represent,
respectively, terminal buds that are either actively
growing and creating new segments or segments that
have stopped proliferating. The presence of CCN5 in
mesenchymal cells suggests that it may be important for
signaling epithelial growth, such as defining barriers or
edges of the bronchiole. Although CCN5 was expressed
Fig. 9 CCN5 mRNA is expressed in all GD14.5 fetal mouse organs.
RNA was harvested from pooled GD14.5 C57BL/6 mouse organs,
reverse transcribed, and PCR was performed using primers specific to
mouse CCN5 or Tbp (loading control) on mRNA treated with (+RT)
or without (−RT) reverse transcriptase. (negative signs) no template
control (positive signs) plasmid containing mouse CCN5 cDNA (a)
maternal uterus (b) placenta (c) lung (d) limbs and tails (e) umbilical
cord (f) intestine (g) heart (h) liver (i) carcass (j) head (k) maternal
aorta
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in both mesenchymal and epithelial cells of the develop-
ing airway, CCN2 was observed only in the epithelial
cells. The interactions between epithelial and mesenchy-
mal cells are critical in airway formation and differenti-
ation (Evans et al. 1999; Van Tuyl and Post 2003). In
addition, CCN5 was present in larger bronchi, and no
CCN2 was present. The primary bronchioles and major
airways form earlier in development and are thus relatively
quiescent at this stage (Van Tuyl and Post 2003). The
presence of high levels of CCN2 in some terminal
bronchiolar buds but not others suggests that CCN2 might
be required only in actively branching bronchioles, and the
continued presence of CCN5 throughout both actively
branching and stable bronchioles suggests it might be
required throughout their development.
In the musculoskeletal system, it is interesting to note
that the pattern of integrin αv protein expression is
concentrated at the extremities of apical myotubes marking
their shape (Hirsch et al. 1994; Tarone et al. 2000). The
pattern of CCN5 expression was similar, suggesting that it
may participate in the organization of the myotendinous
junction. Integrin binding has been demonstrated in other
CCN family members and has been implicated in angio-
genesis and matrix attachment (reviewed in Lau and Lam
Table 1 CCN expression in mammalian development
Paper 1 2 3 4 5 2 6 7 7 8 9 10 7 7
CCN studied CCN1 CCN1 CCN2 CCN2 CCN2 CCN2 CCN2 CCN2 CCN2 CCN3 CCN3 CCN4 CCN5 CCN5
Mouse x x x x x x x x x x x
Rat x
Human x x x
ISH x x x x x x x




+ + − + + + + + + ++ − − + +
Cardiac
muscle
− + − + + + + + − − + +/− + +
Endothelia − +/− + + + + + + + − + − + +
Nervous system
Brain − + − + + − + + − − + − + −
Meninges − nd + nd + nd + + nd − + − + nd
Skeletal system, muscle
Cartilage + + ++ + + − − + nd − + + + nd
Bone + + − nd + − − + − − − + + +
Perichondrium +/− nd + nd + nd +/− +/− nd − + + + nd
Skeletal
muscle
− nd − nd nd + + +/− − ++ ++ − ++ +/−
Skin
Epidermis − + − nd nd +/− − ++ ++ − nd − ++ ++
Hair − + − nd nd + nd + ++ + nd − + ++
Lung
Bronchioles − + − nd nd + ++ ++ − ++ + − + +/−
Blood vessels − + ++ nd nd + ++ +/− nd nd + − + nd
Secretory tissues
Liver − nd − nd nd nd ++ + + − +/− − + +
Kidney − − − nd nd + ++ +/− +/− − ++ − + +
Reproductive
organs
− nd nd nd nd nd nd − − nd + − + +/−
Placenta ++ + nd nd nd + + nd − nd nd − nd ++
Digestive tract − − − + nd − ++ ++ +/− nd + − + +
Endocrine
glands
− − − nd nd − + +/− − nd + − +/− +
CCN expression patterns in development. Key: ++, very strong; +, strong; +/−, weak; –, absent; nd, not determined; IHC, immunohistochemistry;
ISH, in situ hybridization. Papers: (1) O’Brien and Lau 1992 (2) Kireeva et al. 1997 (3) Friedrichsen et al. 2003 (4) Ivkovic et al. 2003 (5) Lopes
et al. 2004 (6) Surveyor and Brigstock 1999 (7) Data presented in this article (8) Natarajan et al. 2000 (9) Kocialkowski et al. 2001 (10) French et
al. 2004. Rat and mouse expression patterns were identical in (9). Protein tracked mRNA expression in (9) and (10).
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1999; Lau and Lam 2005; Leask and Abraham 2006). Our
findings suggest that integrin αv may be important for
CCN5 signaling.
In contrast to previous observations in 2 week old rats,
we did not detect CCN2 in osteocytes, suggesting that the
role of CCN2 in this cell type may not emerge until bones
have fully formed (Safadi et al. 2003). This may represent a
species or age difference in CCN2 expression; however,
because only a small core of human fetal bone was
examined, it cannot be concluded that CCN2 is not
expressed in fetal human bone osteocytes. CCN2 expres-
sion in hypertrophic chondrocytes in both fetal and healing
cartilage and bone is thought to feed back on proliferating
chondrocytes to induce their maturation (Kubota and
Takigawa 2007; Takigawa et al. 2003; Takigawa et al.
2005; Yamaai et al. 2005). The presence of CCN5 in the
proliferating and calcification zones of ossifying bones
suggests that it has an important role in ossification. The
expression pattern we observe is similar to that reported by
Kumar et al. (1999). The opposite expression patterns of
CCN2 and CCN5 in hypertrophic chondrocytes suggest
that these proteins may be coordinately regulated during
ossification.
We observed a change from patchy to uniform CCN5
expression in the liver as gestational age increased. This
may reflect the change of liver function as a hematopoietic
organ in younger fetuses to a non-hematopoietic organ in
5 month old fetuses (Tavian and Peault 2005). At GD16 in
mice, approximately 40% of the liver volume is dedicated
to hematopoiesis (Dzierzak and Medvinsky 1995). It is
noteworthy that liver hematopoiesis remains important
throughout mouse fetal development and is present at much
lower levels in the 5 month human fetus, consistent with
the hypothesis that loss of hepatic CCN2 expression
correlates with the loss of hematopoiesis in human fetal
tissue. CCN2 protein and mRNA expression has been
reported to be low but present in normal adult rat tissue (Li
et al. 2006).
CCN2 protein and mRNA expression has been reported
to be low in intestinal smooth muscle unless there is a
fibrotic stimulus such as TGF-β, radiation treatment, or
Crohn’s disease (Beddy et al. 2006; Haydont et al. 2005;
Vozenin-Brotons et al. 2003). In our study CCN2 was
initially highly expressed in intestinal development and
expression was reduced to lower levels in older human and
mouse intestine. Because of our previous studies of the
differential expression of CCN5 relative to growth state of
the cell, we expected to find that rapidly proliferating cells
would not express high levels of CCN5, and quiescent or
growth-arrested cells would express large amounts of
CCN5. This pattern is present in the colonic epithelium,
where the proliferating cells in the crypts of the villi did not
express CCN5, but in non-proliferating cells in the villi tips
CCN5 levels were high. However, in contrast to the
situation observed for vascular SMC, in which CCN2 is
expressed in proliferating but not quiescent cells and CCN5
is the opposite expression pattern (Fan et al. 2000; Lake
et al. 2003), both CCN2 and CCN5 were expressed in a
similar pattern in the colonic epithelium. This suggests that
although CCN5 and CCN2 both are needed for cell growth
control, they are not necessarily regulated in a complemen-
tary fashion in all cell types and key mechanistic differ-
ences may exist in CCN protein biology between
mesenchymal and epithelial cells.
In the kidney and urogenital system, the terminal buds of
kidney metanephric tubules express both CCN2 or CCN5
terminal ends of tubules but not throughout the tubules,
suggesting that these proteins may work in concert to
regulate terminal bud proliferation and branching. The lack
of CCN5 in the endothelial cells of the glomerular tufts
suggests that CCN5 has a different function in the tightly
coupled endothelial cells of large vessels compared to those
of the more permeable glomerular tufts. CCN2 mRNA and
protein expression has been reported to be low but present
in healthy adult kidney (Riser et al. 2005).
We detected high levels of CCN2 and CCN5 throughout
GD16 skin and oral epithelium. Kireeva et al. detected
CCN2 in skin during early gestation and in the dermis of
tongue and tail, and Surveyor and Brigstock detected CCN2
only in oral epithelium (see Table 1) (Kireeva et al. 1997;
Surveyor and Brigstock 1999). This discrepancy might be
caused by differences in antibody sensitivity. The antibody
that detected CCN2 both in mouse and human fetal skin in
this report also detects CCN2 in normal adult human skin
(Carulli et al. 2005).
CCN5 has been observed to be expressed in secretory
structures, including in the endometrial glands (Mason et al.
2004a), thus it is not unexpected that CCN5 protein was
found in most secretory glands including the exocrine
pancreas and thyroid. CCN5 is expressed in many steroid-
secreting cells during human development, including
human testicular Leydig cells and the cortisol-secreting
cells of the adrenal glands. The low expression levels of
CCN5 in fetal uterine smooth muscle and glands was in
agreement with the hypothesis that CCN5 protein increases
as smooth muscle cells differentiate because it is expressed
at high levels in both adult human and rat uterine tissue
(Mason et al. 2004a, b). Although CCN5 is highly
expressed in response to high estrogen levels in the adult,
this tissue may not have the ability to regulate CCN5 in
response to estrogen levels until sexual maturity is reached.
In most cell and tissue types, CCN5 expression was
observed primarily in the cytoplasm and periphery of cells
as previously observed in cultured vascular SMC (Lake
et al. 2003). In addition, we also observed nuclear
localization of CCN5 in some cells. Nuclear localization
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was particularly prominent in the cells of the spinal cord
and adrenal gland. Both CCN2 and CCN3 have been
detected in the nucleus and are likely to help regulate
transcription (Gellhaus et al. 2004; Perbal 1999; Wahab
et al. 2001). Amino-truncated but not full length CCN3 has
been detected in cell nuclei, and CCN3–Gal4 fusion
proteins can reduce transcription of reporter genes with
Gal4 binding sites (Perbal 1999). CCN3 has been shown to
interact with the rpb7 subunit of RNA polymerase in a
yeast two hybrid system (Perbal 1999) However, the C-
terminal domain of CCN3 has been identified as the
responsible module for both nuclear localization because
it contains an NLS and also transcription repression
(Planque et al. 2006). As CCN5 lacks the C-terminal
module this suggests that CCN5 may be locating to the
nucleus by a novel mechanism (Planque et al. 2006). The
variation in subcellular localization of CCN5 among
different cell types supports the idea that CCN5 may have
several different functions within the cell.
The unexpectedly broad expression pattern of CCN5 in
most embryonic and fetal tissues, combined with its
increasingly tissue-specific expression with developmental
age, suggests cell- and tissue-specific functions for CCN5.
Furthermore, we observe CCN5 expression on the cell
periphery, in the cytoplasm, and in the nucleus. These
findings point to a complex set of conditions and
parameters that are likely to regulate CCN5 and its
biological roles, including growth state, hormonal influen-
ces, extracellular milieu, cell cycle position, reproductive
status, developmental stage, contact/density, cytokine ex-
posure, adhesion, disease, and other influences. The finding
that CCN5, like other CCN proteins, is localized in the
nucleus represents another layer of complexity and leads to
the hypothesis that CCN5 regulates transcription of genes
controlling cell proliferation and motility. Furthermore,
while our data rule out the original premise that CCN5
and CCN2 are generally expressed in coordinately regulat-
ed fashion, it still leaves open the possibility that in certain
tissues, notably bone and cartilage, these CCN proteins may
work in concert to regulate development and function.
Efforts to elucidate the mechanisms and molecules
regulating the developmental and physiologic role(s) of
CCN5 are underway in several laboratories. The results
presented in this communication should provide a firm
foundation for additional hypothesis generation and inter-
pretation of data obtained by other experimental
approaches.
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